A phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours

被引：0
|
作者：
Tolcher, A. W. [1 ]
Falchook, G. [2 ]
Bendell, J. C. [3 ]
Ungar, D. [4 ]
Boni, J. [4 ]
Chao, G. [4 ]
Patel, M. R. [3 ,5 ]
机构：
[1] NEXT Oncol, Clin Res, San Antonio, TX USA
[2] HealthONE, Drug Dev Program, Sarah Cannon Res Inst, Denver, CO USA
[3] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[4] ADC Therapeut Inc, Clin Dev, Murray Hill, NJ USA
[5] Florida Canc Specialists, Sarasota Drug Dev Unit, Sarasota, FL USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
468P
引用
收藏
页码：176 / +
页数：2
相关论文
共 50 条
  • [31] Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Hamid, Omid
    Shum, Elaine
    Wise, David R.
    Balar, Arjun Vasant
    Weber, Jeffrey S.
    LoRusso, Patricia
    Shafi, Saba
    Rimm, David L.
    Tolcher, Anthony W.
    Basudhar, Debashree
    Dujka, Melanie Elizabeth
    Heller, Kevin N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
    Jason D. Lickliter
    Mark Voskoboynik
    Linda Mileshkin
    Hui K. Gan
    Ganessan Kichenadasse
    Kathy Zhang
    Maggie Zhang
    Zhiyu Tang
    Michael Millward
    British Journal of Cancer, 2022, 126 : 310 - 310
  • [33] A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TAK-169 in Patients With Relapsed or Refractory Multiple Myeloma
    Kumar, Shaji
    Mamuye, Admasu
    Dabovic, Kristina
    Wang, Jingyuan
    Roy, Vivek
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 : S10 - S11
  • [34] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
    Harvey, R. Donald
    Falchook, Gerald Steven
    Naqash, Abdul Rafeh
    Kim, Joseph W.
    Dowlati, Afshin
    Le Bruchec, Yvan
    Coudert, Isabelle
    Ervin-Haynes, Annette L.
    Sommerhalder, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Janku, Filip
    Tian, Linjie
    Luke, Jason J.
    Shum, Elaine
    Shin, John
    Weiss, Ido
    Liu, Linda N.
    Files, Dallas
    Langermann, Solomon
    Myint, Han
    Bilusic, Marijo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
    Li, Xiaoyu
    Qiu, Meng
    Wang, ShengJun
    Zhu, Hong
    Feng, Bi
    Zheng, Li
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (03) : 593 - 604
  • [37] A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors
    Leong, Stephen
    Moss, Rebecca A.
    Bowles, Daniel W.
    Ware, Joseph A.
    Zhou, Jing
    Spoerke, Jill M.
    Lackner, Mark R.
    Shankar, Geetha
    Schutzman, Jennifer L.
    van der Noll, Ruud
    Voest, Emile E.
    Schellens, Jan H. M.
    ONCOLOGIST, 2017, 22 (12): : 1491 - 1499
  • [38] A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
    Xiaoyu Li
    Meng Qiu
    ShengJun Wang
    Hong Zhu
    Bi Feng
    Li Zheng
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 593 - 604
  • [39] Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
    Toshihiko Doi
    Narikazu Boku
    Yusuke Onozawa
    Keishiro Takahashi
    Osamu Kawaguchi
    Atsushi Ohtsu
    Investigational New Drugs, 2020, 38 : 1390 - 1399
  • [40] An Open-Label, Sequential Dose-Escalation, Safety, and Tolerability Study of Rimabotulinumtoxinb in Subjects With Cervical Dystonia
    Chinnapongse, Robert
    Pappert, Eric J.
    Evatt, Marian
    Freeman, Alan
    Birmingham, William
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2010, 120 (11) : 703 - 710
12345